The López-Belmonte family, the principal shareholders of Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”), have increased their interest in the company’s share capital to 63.107% through their investment vehicle Norbel Inversiones, S.L., which has thus become the direct holder of 35,383,462 of ROVI’s shares.

Juan López-Belmonte Encina said: “This increase in the interest held by Norbel Inversiones, S.L. in ROVI’s share capital reflects the López-Belmonte family’s clear bet on the company and our confidence in ROVI’s business model and its future prospects”.